Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. the trough level is not enough

Pediatric Transplantation

Volumn 13, Issue 4, 2009, Pages 444-450

  Schrauder, A ^b   Saleh, S ^c   Sykora, K W ^a   Hoy, H ^a   Welte, K ^a   Boos, J ^c   Hempel, G ^c,d   Grigull, L ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cyclosporine A; Graft vs. host disease; Monitoring; Pediatric; Pharmacokinetic

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; BUSULFAN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FOLINIC ACID; ITRACONAZOLE; METHOTREXATE; METRONIDAZOLE; PHENYTOIN; TOBRAMYCIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MONITORING; EXPERIMENTAL MODEL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; MYCOSIS; PRESCHOOL CHILD; SCHOOL CHILD; SEIZURE; STEM CELL TRANSPLANTATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFUSIONS, INTRAVENOUS; MALE; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 65549143257     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00968.x     Document Type: Article

References (28)

1. Peters C, Minkov M, Gadner H, et al. Statement of current majority practices in graft-vs.-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000 : 26 : 405 411. (Pubitemid 30649556)
2. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukaemia. Blood 1991 : 77 : 1423 1428.
3. Byrne JL, Stainer C, Hyde H, et al. Low incidence of acute graft-vs.-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant 1998 : 22 : 541 545. (Pubitemid 28445752)
4. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate vs. cyclosporin A as graft vs. host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO-EBMT randomized trial. Blood 2000 : 96 : 1690 1697. (Pubitemid 30661050)
5. Kagawa Y, Sawada J, Yamada S, et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003 : 26 : 1115 1119. (Pubitemid 40012575)
6. Takahata M, Hashino S, Izumiyama K, Chiba K, Suzuki S, Asaka M. Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-vs.-host disease by tacrolimus. Bone Marrow Transplant 2001 : 28 : 713 715. (Pubitemid 33014608)
7. Svennilson J, Remberger M, Ringden O. Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children. Pediatr Transplant 2003 : 7 : 130 136. (Pubitemid 36514069)
8. Hunter AE, Bessell EM, Russell NH. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant 1992 : 10 : 431 434.
9. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: What every transplanter needs to know. Bone Marrow Transplant 2004 : 33 : 137 152. (Pubitemid 38180925)
10. Grevel J. Area-under-the-curve vs. trough level monitoring of cyclosporine concentration: Critical assessment of dosage adjustment practices and measurement of clinical outcome. Ther Drug Monit 1993 : 15 : 488 491. (Pubitemid 23347238)
11. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993 : 54 : 205 218. (Pubitemid 23265051)
12. Luck R, Boger J, Kuse E, Klempnauer J, Nashan B. Achieving adequate cyclosporine exposure in liver transplant recipients: A novel strategy for monitoring and dosing using intravenous therapy. Liver Transpl 2004 : 10 : 686 691. (Pubitemid 38628231)
13. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax DM, Kaplan B. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. J Clin Pharmacol 1999 : 39 : 166 171. (Pubitemid 29068162)
14. Nashan B, Bock A, Bosmans JL, et al. Use of Neoral C monitoring: A European consensus. Transplant Int 2005 : 18 : 768 778. (Pubitemid 41726805)
15. Donnelly JP, Blijlevens NM, Schattenberg AV. Monitoring cyclosporine using blood drawn via a central venous catheter. Bone Marrow Transplant 2003 : 32 : 1037. (Pubitemid 37461542)
16. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005 : 27 : 116 122. (Pubitemid 40463636)
17. Yin OQ, Lau SK, Chow MS. Population pharmacokinetics of cyclosporine in Chinese cardiac transplant recipients. Pharmacotherapy 2006 : 26 : 790 797. (Pubitemid 43807630)
18. Bourgoin H, Paintaud G, Buchler M, et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 2005 : 59 : 18 27. (Pubitemid 40040092)
19. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: Comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004 : 26 : 23 30. (Pubitemid 38140906)
20. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006 : 45 : 905 922. (Pubitemid 44299827)
21. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007 : 29 : 96 102. (Pubitemid 46279882)
22. Brynskov J, Freund L, Campanini MC, Kampmann JP. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol 1992 : 27 : 961 967.
23. Karlsson MO, Sheiner LB. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J Pharmacokin Biopharm 1993 : 21 : 735 750. (Pubitemid 24052760)
24. Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-vs.-host disease after pediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003 : 329 : 881 887. (Pubitemid 37369265)
25. David-Neto E, Lemos FB, Furusawa EA, et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol 2000 : 11 : 343 349. (Pubitemid 30064858)
26. Teuffel O, Schrauder A, Sykora KW, et al. The impact of cyclosporin A on acute graft-vs.-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Bone Marrow Transplant 2005 : 36 : 145 150. (Pubitemid 41030630)
27. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001 : 97 : 2962 2971.
28. Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-vs.-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001 : 27 : 727 730. (Pubitemid 32409448)